Drugs / ACTINIUM DOTATATE

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06411301 Oct 2024 → Oct 2026 plasma cell myeloma Jules Bordet Institute Withdrawn No outcome recorded
Phase 1 NCT05595460 Oct 2022 → Jul 2027 expected small cell lung carcinoma RayzeBio, Inc. Active not recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07150806 Nov 2025 → Dec 2026 expected meningioma Joshua Palmer Recruiting No outcome recorded
Phase 1/2 NCT06590857 Jul 2024 → Oct 2028 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer RayzeBio, Inc. Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT05477576 Mar 2022 → Dec 2026 expected carcinoid tumor, pancreatic neuroendocrine tumor RayzeBio, Inc. Recruiting No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as ACTINIUM DOTATATE ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772
Known as 225Ac-DOTATATE “Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally...” NCT06590857
2

“I. To estimate the efficacy of 225Ac-DOTATATE (RYZ101) therapy in the treatment of patients with progressive or recurrent grade 1-3 intracranial meningioma as measured by the...” NCT07150806

NCT06411301

Known as 225ac-oxodotreotide ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772
Known as ACTINIUM AC 225 DOTATATE ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772
Known as Actinium oxodotreotide ac-225 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772
Known as Oxodotreotide ac-225 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772
Known as RYZ101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05595460
3

NCT07150806

NCT05477576

NCT06590857

Modality Other / unclassified “It is a type of radioconjugate and a type of somatostatin analog.” NCT07150806
Route Intravenous “Two intravenous infusions every 6 weeks (Q6W)” NCT06411301